RxDoctor Payments Data

Daniel Hardy, MD

Family Medicine · Los Banos, CANPI 1689679045

Payments from drug & device makers

$2,026in general payments, 2019–2025

Across 116 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$511
  • AstraZeneca$316
  • Novo Nordisk$278
  • Boehringer Ingelheim$254
  • GSK$178
  • Corcept Therapeutics$102
  • plus $388 from 11 others

What the payments were for

  • Food & beverage$2,00699%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,026 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$40,385
Medicare patients
108
Services billed
427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$127,202
FarxigaDapagliflozin Propanediol96$88,312
JardianceEmpagliflozin69$71,777
TrulicityDulaglutide68$68,568
MounjaroTirzepatide41$45,735
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$33,978
RexultiBrexpiprazole19$32,904
EliquisApixaban44$32,280
RybelsusSemaglutide26$31,441
XareltoRivaroxaban26$28,239
MyrbetriqMirabegron33$20,400
ViberziEluxadoline12$18,612
FanaptIloperidone11$18,217
LinzessLinaclotide14$16,374
JanuviaSitagliptin Phosphate14$15,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$278$158,642123 claims
Lilly USA, LLCTrulicity, Mounjaro$511$114,303109 claims
AstraZenecaFarxiga, Symbicort$316$91,223108 claims
Boehringer IngelheimJardiance$254$71,77769 claims
GSKTrelegy Ellipta, Breo Ellipta$178$43,55162 claims
Otsuka America Pharmaceutical, Inc.Rexulti$49$32,90419 claims
PfizerEliquis$79$32,28044 claims
Astellas Pharma US IncMyrbetriq$24$20,40033 claims
MerckJanuvia$16$15,21414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Los Banos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →